Endpoints and clinical trial design for
โ
Arun J. Sanyal; Elizabeth M. Brunt; David E. Kleiner; Kris V. Kowdley; Naga Chal
๐
Article
๐
2011
๐
John Wiley and Sons
๐
English
โ 155 KB
๐ 1 views
Nonalcoholic fatty liver disease is a common cause of chronic liver disease in the general population. Nonalcoholic steatohepatitis (NASH), the aggressive form of nonalcoholic fatty liver disease, is associated with an increased risk of liver-related mortality and cardiovascular disease. At present,